CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Enforcing GLUT3 expression in CD8(+) T cells improves fitness and tumor control by promoting glucose uptake and energy storage.
Enforcing GLUT3 expression in CD8(+) T cells improves fitness and tumor control by promoting glucose uptake and energy storage.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
尽管过继性T细胞疗法(ACT)在对抗某些血液系统恶性肿瘤方面取得了巨大成功,但并非所有患者都有应答,一部分患者会经历复发,而大多数实体瘤的有效ACT仍然难以实现。为了改善对ACT的应答,必须克服实体瘤微环境(TME)中的抑制性屏障,包括营养物质可用性不足。
在此,我们探索了强制表达高亲和力葡萄糖转运体GLUT3如何影响肿瘤靶向T细胞。在原代小鼠CD8+ T细胞中过表达GLUT3增强了葡萄糖摄取,增加了糖原和脂肪酸储存,并与线粒体适应性增强、ROS水平降低、抗凋亡蛋白Mcl-1丰度升高以及对应激的抵抗力增强相关。
重要的是,GLUT3-OT1 T细胞对B16-OVA黑色素瘤肿瘤提供了更优的控制,并且在同一模型中显著改善了生存。此外,一部分接受治疗的小鼠被治愈,并对再次攻击具有保护作用,这表明T细胞长期存续和记忆形成。
因此,强制表达GLUT3是改善代谢适应性并在ACT背景下维持CD8+ T细胞效应功能的一种有前景的策略。
Despite the tremendous success of adoptive T-cell therapies (ACT) in fighting certain hematologic malignancies, not all patients respond, a proportion experience relapse, and effective ACT of most solid tumors remains elusive. In order to improve responses to ACT suppressive barriers in the solid tumor microenvironment (TME) including insufficient nutrient availability must be overcome.
Here we explored how enforced expression of the high-affinity glucose transporter GLUT3 impacted tumor-directed T cells. Overexpression of GLUT3 in primary murine CD8 + T cells enhanced glucose uptake and increased glycogen and fatty acid storage, and was associated with increased mitochondrial fitness, reduced ROS levels, higher abundance of the anti-apoptotic protein Mcl-1, and better resistance to stress.
Importantly, GLUT3-OT1 T cells conferred superior control of B16-OVA melanoma tumors and, in this same model, significantly improved survival.
Moreover, a proportion of treated mice were cured and protected from re-challenge, indicative of long-term T cell persistence and memory formation. Enforcing expression of GLUT3 is thus a promising strategy to improve metabolic fitness and sustaining CD8 + T cell effector function in the context of ACT.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。